Pituitary

, Volume 20, Issue 1, pp 116–120 | Cite as

T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective

Article
  • 485 Downloads

Abstract

T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas that are T2-hypointense are more common, are smaller and are less likely to invade the cavernous sinus compared to the T2-iso and hyperintense tumors. T2-hypointense tumors are also accompanied by higher IGF1 values at baseline. When presurgical somatostatin receptor ligand (SRL) therapy is administered, T2-hypointense adenomas have better hormonal responses and have greater tumor shrinkage. Adjuvant SRL therapy of patients with T2-hypointense tumors that are uncured by surgery is also associated with a better hormonal response. We review the studies that have dealt with the T2-weighted signal intensity of GH-secreting pituitary tumors and elaborate on the details and nuances of this promising avenue of research.

Keywords

Acromegaly MRI T2-weighted signal intensity Somatostatin receptor ligands 

Notes

Acknowledgements

The authors would like to acknowledge Dr. Adrian Daly for discussions about the topic.

Compliance with Ethical Standards

Conflict of interest

The authors report no conflict of interest.

References

  1. 1.
    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. doi: 10.1210/jc.2014-2700 CrossRefPubMedGoogle Scholar
  2. 2.
    Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661–666. doi: 10.1530/eje-09-0908 CrossRefPubMedGoogle Scholar
  3. 3.
    Fougner SL, Bollerslev J, Svartberg J, Oksnes M, Cooper J, Carlsen SM (2014) Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol/Eur Fed Endocr Soc 171(2):229–235. doi: 10.1530/eje-14-0249 CrossRefGoogle Scholar
  4. 4.
    Jaffrain-Rea M-L, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen J-F, D’Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr-relat Cancer 16(3) 1029–1043.CrossRefPubMedGoogle Scholar
  5. 5.
    Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, Gadelha MR (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr-relat Cancer 19(3) L25–29. doi: 10.1530/erc-12-0020 CrossRefPubMedGoogle Scholar
  6. 6.
    Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93(4):1412–1417. doi: 10.1210/jc.2007-1358 CrossRefPubMedGoogle Scholar
  7. 7.
    Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol/Eur Fed Endocr Soc 158(3):295–303. doi: 10.1530/eje-07-0562 CrossRefGoogle Scholar
  8. 8.
    Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis, L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol/Eur Fed Endocr Soc 174(2):241–250. doi: 10.1530/eje-15-0832 CrossRefGoogle Scholar
  9. 9.
    Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295. doi: 10.1210/jc.2005-0998 CrossRefPubMedGoogle Scholar
  10. 10.
    Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers, A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373–E383. doi: 10.1210/jc.2009-2556 CrossRefPubMedGoogle Scholar
  11. 11.
    Beckers A, Lodish M, Giampaolo T, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong C, Caberg JH, Verrua E, Naves LA, Cheetham T, Young J, Lysy P, Petrossians P, Cotterill A, Shah N, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barcelos Barra G, Casulari LA, Neggers S, Salvatori R, Jaffrain-Rea ML, Zacharin M, Lecumberri Santamaria B, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, Collins MT, Bonneville JF, Quezado M, Chittiboina P, Oldfield E, Bours V, Liu P, de Herder WW, Pellegata NS, Lupski JR, Daly AF, Stratakis CA (2015) X-linked acrogigantism (X-LAG) syndrome: clinical profile and therapeutic responses. Endocr-relat Cancer. doi: 10.1530/erc-15-0038 PubMedCentralGoogle Scholar
  12. 12.
    Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P (1998) Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 83(5):1604–1610. doi: 10.1210/jcem.83.5.4797 PubMedGoogle Scholar
  13. 13.
    Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone–producing and non–growth hormone–producing pituitary adenomas: imaging characteristics and pathologic correlation1. Radiology 228(2):533–538CrossRefPubMedGoogle Scholar
  14. 14.
    Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr-relat Cancer 22(2) 169–177. doi: 10.1530/erc-14-0305 CrossRefPubMedGoogle Scholar
  15. 15.
    Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978CrossRefPubMedGoogle Scholar
  16. 16.
    Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77(1):72–78CrossRefGoogle Scholar
  17. 17.
    Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schofl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr-relat Cancer 23(11) 871–881. doi: 10.1530/erc-16-0356 CrossRefPubMedGoogle Scholar
  18. 18.
    Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X, Li Y, Zhang Z, Ye H, He M, Lu B, Yao Z, Lu Y, Qiao N, Ye Z, Zhang Y, Yang Y, Zhao Y, Wang Y (2016) Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. doi: 10.1007/s00234-016-1728-4 Google Scholar
  19. 19.
    Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343. doi: 10.1007/s12020-015-0766-8 CrossRefPubMedGoogle Scholar
  20. 20.
    Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863. doi: 10.1210/jc.2004-1093 CrossRefPubMedGoogle Scholar
  21. 21.
    Bakhtiar Y, Hanaya R, Tokimura H, Hirano H, Oyoshi T, Fujio S, Bohara M, Arita K (2014) Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma. Pituitary 17(2):142–149. doi: 10.1007/s11102-013-0479-z CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Endocrinology, Centre Hospitalier Universitaire de LiègeUniversité de LiègeLiègeBelgium
  2. 2.Department of Neuroradiology, Centre Hospitalier Universitaire de LiègeUniversité de LiègeLiègeBelgium

Personalised recommendations